[A21-07] Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Addendum to Commission A20-74
Last updated 18.02.2021
Project no.:
A21-07
Commission:
Commission awarded on 13.01.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Solid tumours expressing an NTRK gene fusion, disease locally advanced or metastatic or where surgical resection is likely to result in severe morbidity: patients 12 years of age and older who have not received a prior NTRK inhibitor and who have no satisfactory treatment options
Conclusion of dossier assessment A20-74 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-74 | Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-02-18: A G-BA decision was published.